nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—HTR1D—autistic disorder	0.334	0.434	CbGaD
Atomoxetine—HTR1B—autistic disorder	0.198	0.258	CbGaD
Atomoxetine—SLC6A4—autistic disorder	0.134	0.174	CbGaD
Atomoxetine—HTR2A—autistic disorder	0.103	0.134	CbGaD
Atomoxetine—HTR1B—telencephalic ventricle—autistic disorder	0.00416	0.0472	CbGeAlD
Atomoxetine—SLC6A3—telencephalic ventricle—autistic disorder	0.00412	0.0468	CbGeAlD
Atomoxetine—HTR1D—telencephalic ventricle—autistic disorder	0.00402	0.0457	CbGeAlD
Atomoxetine—HTR2C—telencephalic ventricle—autistic disorder	0.00399	0.0453	CbGeAlD
Atomoxetine—HTR2A—cerebellar cortex—autistic disorder	0.00344	0.039	CbGeAlD
Atomoxetine—NPY1R—forebrain—autistic disorder	0.00256	0.0291	CbGeAlD
Atomoxetine—HTR2A—pons—autistic disorder	0.00243	0.0276	CbGeAlD
Atomoxetine—NPY1R—telencephalon—autistic disorder	0.00235	0.0267	CbGeAlD
Atomoxetine—HTR2A—telencephalic ventricle—autistic disorder	0.002	0.0227	CbGeAlD
Atomoxetine—SLC6A3—hindbrain—autistic disorder	0.00195	0.0221	CbGeAlD
Atomoxetine—HTR6—forebrain—autistic disorder	0.0018	0.0204	CbGeAlD
Atomoxetine—SLC6A4—hindbrain—autistic disorder	0.00178	0.0203	CbGeAlD
Atomoxetine—HTR6—telencephalon—autistic disorder	0.00166	0.0188	CbGeAlD
Atomoxetine—NPY1R—head—autistic disorder	0.00147	0.0166	CbGeAlD
Atomoxetine—NPY1R—nervous system—autistic disorder	0.00139	0.0158	CbGeAlD
Atomoxetine—NPY1R—central nervous system—autistic disorder	0.00134	0.0152	CbGeAlD
Atomoxetine—HTR1B—brainstem—autistic disorder	0.00112	0.0128	CbGeAlD
Atomoxetine—SLC6A3—brainstem—autistic disorder	0.00112	0.0127	CbGeAlD
Atomoxetine—HTR1D—brainstem—autistic disorder	0.00109	0.0124	CbGeAlD
Atomoxetine—HTR1B—forebrain—autistic disorder	0.00109	0.0123	CbGeAlD
Atomoxetine—HTR2C—brainstem—autistic disorder	0.00108	0.0122	CbGeAlD
Atomoxetine—SLC6A3—forebrain—autistic disorder	0.00108	0.0122	CbGeAlD
Atomoxetine—NPY1R—brain—autistic disorder	0.00106	0.0121	CbGeAlD
Atomoxetine—HTR1D—eye—autistic disorder	0.00106	0.012	CbGeAlD
Atomoxetine—HTR1D—forebrain—autistic disorder	0.00105	0.0119	CbGeAlD
Atomoxetine—HTR2C—forebrain—autistic disorder	0.00104	0.0118	CbGeAlD
Atomoxetine—HTR6—head—autistic disorder	0.00103	0.0117	CbGeAlD
Atomoxetine—SLC6A4—brainstem—autistic disorder	0.00102	0.0116	CbGeAlD
Atomoxetine—HTR1B—telencephalon—autistic disorder	0.000998	0.0113	CbGeAlD
Atomoxetine—SLC6A3—telencephalon—autistic disorder	0.00099	0.0112	CbGeAlD
Atomoxetine—SLC6A4—forebrain—autistic disorder	0.000987	0.0112	CbGeAlD
Atomoxetine—HTR6—nervous system—autistic disorder	0.000978	0.0111	CbGeAlD
Atomoxetine—HTR1D—telencephalon—autistic disorder	0.000966	0.011	CbGeAlD
Atomoxetine—HTR2C—telencephalon—autistic disorder	0.000957	0.0109	CbGeAlD
Atomoxetine—HTR2A—hindbrain—autistic disorder	0.000944	0.0107	CbGeAlD
Atomoxetine—HTR6—central nervous system—autistic disorder	0.000941	0.0107	CbGeAlD
Atomoxetine—SLC6A4—telencephalon—autistic disorder	0.000907	0.0103	CbGeAlD
Atomoxetine—SLC6A2—brainstem—autistic disorder	0.0009	0.0102	CbGeAlD
Atomoxetine—SLC6A2—forebrain—autistic disorder	0.000869	0.00986	CbGeAlD
Atomoxetine—CYP2D6—hindbrain—autistic disorder	0.00086	0.00976	CbGeAlD
Atomoxetine—SLC6A2—telencephalon—autistic disorder	0.000799	0.00907	CbGeAlD
Atomoxetine—HTR6—brain—autistic disorder	0.000747	0.00849	CbGeAlD
Atomoxetine—SLC6A4—digestive system—autistic disorder	0.000692	0.00786	CbGeAlD
Atomoxetine—HTR1B—head—autistic disorder	0.000622	0.00706	CbGeAlD
Atomoxetine—SLC6A3—head—autistic disorder	0.000616	0.007	CbGeAlD
Atomoxetine—HTR1D—head—autistic disorder	0.000602	0.00683	CbGeAlD
Atomoxetine—HTR2C—head—autistic disorder	0.000596	0.00677	CbGeAlD
Atomoxetine—Pseudoephedrine—IL2—autistic disorder	0.00059	0.134	CrCbGaD
Atomoxetine—HTR1B—nervous system—autistic disorder	0.000589	0.00669	CbGeAlD
Atomoxetine—SLC6A3—nervous system—autistic disorder	0.000584	0.00664	CbGeAlD
Atomoxetine—CYP2C19—digestive system—autistic disorder	0.000574	0.00652	CbGeAlD
Atomoxetine—HTR1D—nervous system—autistic disorder	0.000571	0.00648	CbGeAlD
Atomoxetine—HTR1B—central nervous system—autistic disorder	0.000567	0.00644	CbGeAlD
Atomoxetine—HTR2C—nervous system—autistic disorder	0.000565	0.00642	CbGeAlD
Atomoxetine—SLC6A4—head—autistic disorder	0.000565	0.00641	CbGeAlD
Atomoxetine—SLC6A3—central nervous system—autistic disorder	0.000563	0.00639	CbGeAlD
Atomoxetine—SLC6A3—cerebellum—autistic disorder	0.00055	0.00625	CbGeAlD
Atomoxetine—HTR1D—central nervous system—autistic disorder	0.000549	0.00624	CbGeAlD
Atomoxetine—HTR2C—central nervous system—autistic disorder	0.000544	0.00618	CbGeAlD
Atomoxetine—HTR2A—brainstem—autistic disorder	0.000541	0.00614	CbGeAlD
Atomoxetine—SLC6A4—nervous system—autistic disorder	0.000536	0.00608	CbGeAlD
Atomoxetine—HTR2A—eye—autistic disorder	0.000527	0.00598	CbGeAlD
Atomoxetine—HTR2A—forebrain—autistic disorder	0.000522	0.00593	CbGeAlD
Atomoxetine—SLC6A4—central nervous system—autistic disorder	0.000516	0.00586	CbGeAlD
Atomoxetine—SLC6A2—head—autistic disorder	0.000497	0.00565	CbGeAlD
Atomoxetine—CYP2D6—brainstem—autistic disorder	0.000493	0.0056	CbGeAlD
Atomoxetine—HTR2A—telencephalon—autistic disorder	0.00048	0.00545	CbGeAlD
Atomoxetine—CYP2D6—forebrain—autistic disorder	0.000476	0.0054	CbGeAlD
Atomoxetine—SLC6A2—nervous system—autistic disorder	0.000472	0.00535	CbGeAlD
Atomoxetine—SLC6A2—central nervous system—autistic disorder	0.000454	0.00515	CbGeAlD
Atomoxetine—HTR1B—brain—autistic disorder	0.00045	0.00511	CbGeAlD
Atomoxetine—SLC6A3—brain—autistic disorder	0.000447	0.00507	CbGeAlD
Atomoxetine—CYP2D6—telencephalon—autistic disorder	0.000437	0.00497	CbGeAlD
Atomoxetine—HTR1D—brain—autistic disorder	0.000436	0.00495	CbGeAlD
Atomoxetine—HTR2C—brain—autistic disorder	0.000432	0.0049	CbGeAlD
Atomoxetine—SLC6A4—brain—autistic disorder	0.000409	0.00465	CbGeAlD
Atomoxetine—HTR2A—digestive system—autistic disorder	0.000366	0.00416	CbGeAlD
Atomoxetine—SLC6A2—brain—autistic disorder	0.00036	0.00409	CbGeAlD
Atomoxetine—CYP3A4—digestive system—autistic disorder	0.000339	0.00385	CbGeAlD
Atomoxetine—CYP2D6—digestive system—autistic disorder	0.000334	0.00379	CbGeAlD
Atomoxetine—HTR2A—head—autistic disorder	0.000299	0.00339	CbGeAlD
Atomoxetine—Reboxetine—SLC6A4—autistic disorder	0.000294	0.0669	CrCbGaD
Atomoxetine—HTR2A—nervous system—autistic disorder	0.000283	0.00322	CbGeAlD
Atomoxetine—HTR2A—central nervous system—autistic disorder	0.000273	0.0031	CbGeAlD
Atomoxetine—CYP2D6—head—autistic disorder	0.000272	0.00309	CbGeAlD
Atomoxetine—Protriptyline—SLC6A4—autistic disorder	0.00027	0.0614	CrCbGaD
Atomoxetine—HTR2A—cerebellum—autistic disorder	0.000267	0.00303	CbGeAlD
Atomoxetine—CYP3A4—nervous system—autistic disorder	0.000262	0.00298	CbGeAlD
Atomoxetine—CYP2D6—nervous system—autistic disorder	0.000258	0.00293	CbGeAlD
Atomoxetine—CYP3A4—central nervous system—autistic disorder	0.000253	0.00287	CbGeAlD
Atomoxetine—Pseudoephedrine—MAOA—autistic disorder	0.000249	0.0565	CrCbGaD
Atomoxetine—CYP2D6—central nervous system—autistic disorder	0.000249	0.00282	CbGeAlD
Atomoxetine—CYP2D6—cerebellum—autistic disorder	0.000243	0.00276	CbGeAlD
Atomoxetine—Methadone—HTR3A—autistic disorder	0.000233	0.053	CrCbGaD
Atomoxetine—Ephedrine—ADRB2—autistic disorder	0.000233	0.0529	CrCbGaD
Atomoxetine—Duloxetine—SLC6A4—autistic disorder	0.000226	0.0514	CrCbGaD
Atomoxetine—HTR2A—brain—autistic disorder	0.000217	0.00246	CbGeAlD
Atomoxetine—CYP2D6—brain—autistic disorder	0.000197	0.00224	CbGeAlD
Atomoxetine—Fluoxetine—SLC6A4—autistic disorder	0.000185	0.0419	CrCbGaD
Atomoxetine—Pseudoephedrine—ADRB2—autistic disorder	0.000177	0.0401	CrCbGaD
Atomoxetine—Duloxetine—HTR2A—autistic disorder	0.000174	0.0395	CrCbGaD
Atomoxetine—Methadone—OPRM1—autistic disorder	0.000168	0.0381	CrCbGaD
Atomoxetine—Propranolol—HTR1B—autistic disorder	0.000167	0.0379	CrCbGaD
Atomoxetine—Pseudoephedrine—SLC6A4—autistic disorder	0.00016	0.0364	CrCbGaD
Atomoxetine—Fluoxetine—HTR2A—autistic disorder	0.000142	0.0322	CrCbGaD
Atomoxetine—Maprotiline—HTR2A—autistic disorder	0.000133	0.0301	CrCbGaD
Atomoxetine—Fenoprofen—PTGS2—autistic disorder	0.00013	0.0295	CrCbGaD
Atomoxetine—Phenoxybenzamine—ADRB2—autistic disorder	0.000126	0.0286	CrCbGaD
Atomoxetine—Propranolol—ADRB2—autistic disorder	0.000124	0.0282	CrCbGaD
Atomoxetine—Methadone—CYP19A1—autistic disorder	0.000119	0.0269	CrCbGaD
Atomoxetine—Nortriptyline—SLC6A4—autistic disorder	0.000104	0.0235	CrCbGaD
Atomoxetine—Desipramine—ADRB2—autistic disorder	9.39e-05	0.0213	CrCbGaD
Atomoxetine—Desipramine—SLC6A4—autistic disorder	8.53e-05	0.0194	CrCbGaD
Atomoxetine—Nortriptyline—HTR2A—autistic disorder	7.96e-05	0.0181	CrCbGaD
Atomoxetine—Ketoprofen—PTGS2—autistic disorder	7.67e-05	0.0174	CrCbGaD
Atomoxetine—Desipramine—HTR2A—autistic disorder	6.56e-05	0.0149	CrCbGaD
Atomoxetine—HTR2A—Signaling Pathways—OPRM1—autistic disorder	1.06e-05	7.62e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PLA2G4A—autistic disorder	1.05e-05	7.55e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—HTR2A—autistic disorder	1.04e-05	7.53e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—ADRB2—autistic disorder	1.04e-05	7.5e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—EXT1—autistic disorder	1.03e-05	7.47e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SLC6A8—autistic disorder	1.03e-05	7.47e-05	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—MAPK1—autistic disorder	1.02e-05	7.39e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—PLA2G4A—autistic disorder	1.02e-05	7.38e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—TCN2—autistic disorder	1.02e-05	7.36e-05	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—PRKCB—autistic disorder	1.01e-05	7.27e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—AVP—autistic disorder	1e-05	7.26e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TSC1—autistic disorder	1e-05	7.25e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—DRD1—autistic disorder	1e-05	7.25e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—autistic disorder	1e-05	7.23e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IGF2—autistic disorder	1e-05	7.22e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—AVP—autistic disorder	9.97e-06	7.2e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IGF2—autistic disorder	9.92e-06	7.17e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—DAO—autistic disorder	9.87e-06	7.13e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NTRK2—autistic disorder	9.76e-06	7.05e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—AVP—autistic disorder	9.76e-06	7.05e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ADA—autistic disorder	9.72e-06	7.03e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IGF2—autistic disorder	9.71e-06	7.02e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—DRD3—autistic disorder	9.71e-06	7.02e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—GZMB—autistic disorder	9.65e-06	6.97e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—RORA—autistic disorder	9.64e-06	6.97e-05	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—PIK3CG—autistic disorder	9.62e-06	6.95e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IL5—autistic disorder	9.51e-06	6.87e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—UPB1—autistic disorder	9.46e-06	6.83e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PLA2G4A—autistic disorder	9.44e-06	6.82e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CALCA—autistic disorder	9.39e-06	6.79e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PLA2G4A—autistic disorder	9.37e-06	6.77e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—OXT—autistic disorder	9.37e-06	6.77e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—HTR1B—autistic disorder	9.37e-06	6.77e-05	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—IL2—autistic disorder	9.2e-06	6.64e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MEF2C—autistic disorder	9.18e-06	6.64e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PLA2G4A—autistic disorder	9.17e-06	6.63e-05	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—POMC—autistic disorder	9.16e-06	6.62e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—PRKCB—autistic disorder	9.13e-06	6.6e-05	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—IL2—autistic disorder	9.13e-06	6.59e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MEF2C—autistic disorder	9.11e-06	6.59e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—MAOB—autistic disorder	9.03e-06	6.53e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—ITGB3—autistic disorder	8.95e-06	6.47e-05	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—IL2—autistic disorder	8.94e-06	6.46e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MEF2C—autistic disorder	8.92e-06	6.45e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—ITGB3—autistic disorder	8.88e-06	6.42e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—RORA—autistic disorder	8.87e-06	6.41e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTM5—autistic disorder	8.79e-06	6.35e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ASMT—autistic disorder	8.79e-06	6.35e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—PIK3CG—autistic disorder	8.74e-06	6.31e-05	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—PRKCB—autistic disorder	8.73e-06	6.31e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TSC1—autistic disorder	8.71e-06	6.29e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—DRD1—autistic disorder	8.71e-06	6.29e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—ITGB3—autistic disorder	8.7e-06	6.28e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—autistic disorder	8.6e-06	6.21e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NTRK2—autistic disorder	8.47e-06	6.12e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—DRD3—autistic disorder	8.44e-06	6.1e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—TPH2—autistic disorder	8.4e-06	6.07e-05	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—PIK3CG—autistic disorder	8.36e-06	6.04e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—HTR2A—autistic disorder	8.36e-06	6.04e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—IL2—autistic disorder	8.35e-06	6.03e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—POMC—autistic disorder	8.32e-06	6.01e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—MAOB—autistic disorder	8.31e-06	6e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PRL—autistic disorder	8.3e-06	5.99e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—HTR2A—autistic disorder	8.29e-06	5.99e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—IL2—autistic disorder	8.29e-06	5.99e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SLC25A12—autistic disorder	8.27e-06	5.97e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—DPYD—autistic disorder	8.26e-06	5.97e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IL5—autistic disorder	8.26e-06	5.97e-05	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—HRAS—autistic disorder	8.21e-06	5.93e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CALCA—autistic disorder	8.16e-06	5.89e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—HTR2A—autistic disorder	8.12e-06	5.87e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—IL2—autistic disorder	8.11e-06	5.86e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SLC19A1—autistic disorder	8.04e-06	5.81e-05	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—POMC—autistic disorder	7.95e-06	5.75e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TSC2—autistic disorder	7.94e-06	5.74e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—PRKCB—autistic disorder	7.93e-06	5.73e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TSC2—autistic disorder	7.88e-06	5.69e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ADRB2—autistic disorder	7.87e-06	5.69e-05	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—IL6—autistic disorder	7.86e-06	5.68e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—LEP—autistic disorder	7.77e-06	5.61e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—APOE—autistic disorder	7.77e-06	5.61e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—autistic disorder	7.76e-06	5.61e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—TPH2—autistic disorder	7.72e-06	5.58e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TSC2—autistic disorder	7.71e-06	5.57e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—LEP—autistic disorder	7.71e-06	5.57e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—APOE—autistic disorder	7.71e-06	5.57e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CACNA1C—autistic disorder	7.68e-06	5.55e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—DPYD—autistic disorder	7.6e-06	5.49e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—PIK3CG—autistic disorder	7.59e-06	5.48e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—APOE—autistic disorder	7.55e-06	5.45e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—LEP—autistic disorder	7.55e-06	5.45e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—AVP—autistic disorder	7.39e-06	5.34e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—POMC—autistic disorder	7.39e-06	5.34e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IGF2—autistic disorder	7.36e-06	5.32e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PRKCB—autistic disorder	7.33e-06	5.29e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PRKCB—autistic disorder	7.27e-06	5.25e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—POMC—autistic disorder	7.22e-06	5.22e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PRL—autistic disorder	7.2e-06	5.21e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ADSL—autistic disorder	7.17e-06	5.18e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PRKCB—autistic disorder	7.12e-06	5.14e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CACNA1C—autistic disorder	7.07e-06	5.1e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—XDH—autistic disorder	7.03e-06	5.08e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PIK3CG—autistic disorder	7.01e-06	5.07e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—APC—autistic disorder	7.01e-06	5.07e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—DHFR—autistic disorder	6.99e-06	5.05e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—APC—autistic disorder	6.96e-06	5.03e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PIK3CG—autistic disorder	6.96e-06	5.03e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PLA2G4A—autistic disorder	6.95e-06	5.02e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—EGF—autistic disorder	6.93e-06	5.01e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—STX1A—autistic disorder	6.9e-06	4.99e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NPAS2—autistic disorder	6.9e-06	4.99e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—EGF—autistic disorder	6.88e-06	4.97e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ADRB2—autistic disorder	6.83e-06	4.94e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—APC—autistic disorder	6.81e-06	4.92e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PIK3CG—autistic disorder	6.81e-06	4.92e-05	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—IL2—autistic disorder	6.77e-06	4.89e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MEF2C—autistic disorder	6.76e-06	4.89e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—EGF—autistic disorder	6.73e-06	4.87e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—POMC—autistic disorder	6.67e-06	4.82e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—TCN2—autistic disorder	6.66e-06	4.82e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—POMC—autistic disorder	6.62e-06	4.78e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ITGB3—autistic disorder	6.59e-06	4.76e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—POMC—autistic disorder	6.48e-06	4.69e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—DHFR—autistic disorder	6.43e-06	4.64e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—AVP—autistic disorder	6.42e-06	4.64e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IGF1—autistic disorder	6.42e-06	4.64e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IGF2—autistic disorder	6.39e-06	4.62e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—MAPK1—autistic disorder	6.39e-06	4.62e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IGF1—autistic disorder	6.37e-06	4.6e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ADA—autistic disorder	6.36e-06	4.59e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—MAPK1—autistic disorder	6.34e-06	4.58e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IGF1—autistic disorder	6.24e-06	4.51e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—MAPK1—autistic disorder	6.21e-06	4.49e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HTR2A—autistic disorder	6.15e-06	4.45e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—IL2—autistic disorder	6.15e-06	4.44e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—SERPINE1—autistic disorder	6.1e-06	4.4e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—SERPINE1—autistic disorder	6.05e-06	4.37e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PLA2G4A—autistic disorder	6.04e-06	4.36e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—SERPINE1—autistic disorder	5.92e-06	4.28e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—autistic disorder	5.89e-06	4.26e-05	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—IL2—autistic disorder	5.88e-06	4.25e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MEF2C—autistic disorder	5.87e-06	4.24e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TSC2—autistic disorder	5.85e-06	4.22e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—RORA—autistic disorder	5.8e-06	4.19e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ITGB3—autistic disorder	5.72e-06	4.14e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—LEP—autistic disorder	5.72e-06	4.13e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—APOE—autistic disorder	5.72e-06	4.13e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CYP19A1—autistic disorder	5.47e-06	3.95e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—MAOB—autistic disorder	5.43e-06	3.93e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PRKCB—autistic disorder	5.39e-06	3.9e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—IL2—autistic disorder	5.34e-06	3.86e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—APC—autistic disorder	5.16e-06	3.73e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PIK3CG—autistic disorder	5.16e-06	3.73e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—autistic disorder	5.14e-06	3.71e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—HRAS—autistic disorder	5.13e-06	3.71e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—EGF—autistic disorder	5.1e-06	3.69e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—HRAS—autistic disorder	5.09e-06	3.68e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—COMT—autistic disorder	5.09e-06	3.68e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TSC2—autistic disorder	5.08e-06	3.67e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GSTP1—autistic disorder	5.06e-06	3.66e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—MAOA—autistic disorder	5.05e-06	3.65e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—TPH2—autistic disorder	5.05e-06	3.65e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CYP19A1—autistic disorder	5.03e-06	3.64e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—HRAS—autistic disorder	4.98e-06	3.6e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—DPYD—autistic disorder	4.97e-06	3.59e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—LEP—autistic disorder	4.97e-06	3.59e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—APOE—autistic disorder	4.97e-06	3.59e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IL2—autistic disorder	4.93e-06	3.56e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CAT—autistic disorder	4.93e-06	3.56e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—POMC—autistic disorder	4.91e-06	3.55e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—IL6—autistic disorder	4.91e-06	3.55e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IL2—autistic disorder	4.9e-06	3.54e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—IL6—autistic disorder	4.87e-06	3.52e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IL2—autistic disorder	4.79e-06	3.46e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—IL6—autistic disorder	4.77e-06	3.45e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IGF1—autistic disorder	4.73e-06	3.42e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—MAPK1—autistic disorder	4.7e-06	3.4e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PRKCB—autistic disorder	4.68e-06	3.38e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—COMT—autistic disorder	4.68e-06	3.38e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GSTP1—autistic disorder	4.66e-06	3.37e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PLA2G4A—autistic disorder	4.65e-06	3.36e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GSTM1—autistic disorder	4.65e-06	3.36e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—MAOA—autistic disorder	4.65e-06	3.36e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PTEN—autistic disorder	4.64e-06	3.35e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CACNA1C—autistic disorder	4.62e-06	3.34e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PTEN—autistic disorder	4.61e-06	3.33e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CAT—autistic disorder	4.53e-06	3.28e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PTEN—autistic disorder	4.51e-06	3.26e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SERPINE1—autistic disorder	4.49e-06	3.24e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PIK3CG—autistic disorder	4.48e-06	3.24e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—APC—autistic disorder	4.48e-06	3.24e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GPX1—autistic disorder	4.46e-06	3.22e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—EGF—autistic disorder	4.43e-06	3.2e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GSTM1—autistic disorder	4.28e-06	3.09e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PLA2G4A—autistic disorder	4.28e-06	3.09e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—POMC—autistic disorder	4.27e-06	3.08e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—DHFR—autistic disorder	4.2e-06	3.04e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—MTHFR—autistic disorder	4.11e-06	2.97e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IGF1—autistic disorder	4.1e-06	2.97e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GPX1—autistic disorder	4.1e-06	2.96e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—MAPK1—autistic disorder	4.09e-06	2.95e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SERPINE1—autistic disorder	3.9e-06	2.82e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—APOE—autistic disorder	3.83e-06	2.77e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—MTHFR—autistic disorder	3.78e-06	2.73e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—HRAS—autistic disorder	3.78e-06	2.73e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MAPK1—autistic disorder	3.77e-06	2.73e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MAPK1—autistic disorder	3.75e-06	2.71e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MAPK1—autistic disorder	3.67e-06	2.65e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IL2—autistic disorder	3.63e-06	2.63e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—IL6—autistic disorder	3.61e-06	2.61e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—APOE—autistic disorder	3.52e-06	2.54e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PIK3CG—autistic disorder	3.46e-06	2.5e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PTEN—autistic disorder	3.42e-06	2.47e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP19A1—autistic disorder	3.29e-06	2.38e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—POMC—autistic disorder	3.29e-06	2.38e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—HRAS—autistic disorder	3.28e-06	2.37e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PIK3CG—autistic disorder	3.18e-06	2.3e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IL2—autistic disorder	3.15e-06	2.28e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—IL6—autistic disorder	3.14e-06	2.27e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—COMT—autistic disorder	3.06e-06	2.21e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTP1—autistic disorder	3.05e-06	2.2e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—MAOA—autistic disorder	3.04e-06	2.2e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—HRAS—autistic disorder	3.03e-06	2.19e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—POMC—autistic disorder	3.03e-06	2.19e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—HRAS—autistic disorder	3.01e-06	2.17e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PTEN—autistic disorder	2.97e-06	2.14e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CAT—autistic disorder	2.96e-06	2.14e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—HRAS—autistic disorder	2.94e-06	2.13e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IL6—autistic disorder	2.9e-06	2.1e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IL6—autistic disorder	2.88e-06	2.08e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IL6—autistic disorder	2.82e-06	2.04e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PLA2G4A—autistic disorder	2.8e-06	2.02e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTM1—autistic disorder	2.8e-06	2.02e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MAPK1—autistic disorder	2.78e-06	2.01e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GPX1—autistic disorder	2.68e-06	1.94e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PTGS2—autistic disorder	2.62e-06	1.9e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—MTHFR—autistic disorder	2.47e-06	1.79e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MAPK1—autistic disorder	2.41e-06	1.74e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PTGS2—autistic disorder	2.41e-06	1.74e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—APOE—autistic disorder	2.3e-06	1.66e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PTEN—autistic disorder	2.29e-06	1.65e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HRAS—autistic disorder	2.23e-06	1.61e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IL6—autistic disorder	2.14e-06	1.54e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PTEN—autistic disorder	2.1e-06	1.52e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PIK3CG—autistic disorder	2.08e-06	1.5e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—POMC—autistic disorder	1.98e-06	1.43e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—HRAS—autistic disorder	1.94e-06	1.4e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IL6—autistic disorder	1.85e-06	1.34e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PTGS2—autistic disorder	1.58e-06	1.14e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PTEN—autistic disorder	1.38e-06	9.94e-06	CbGpPWpGaD
